China reaffirms support to Pakistan on Kashmir

Washington, Apr 28: US President while addressing a news conference on coronavirus pandemic said his administration has launched "very serious investigations" into China's response to the novel coronavirus.

"And we are not happy with China, we are not happy with that whole situation, because we believe it could have been stopped at the source," he said. "It could have been stopped quickly and it wouldn't have spread all over the world," the BBC reported.

Trump has been critical of China as the pandemic has progressed and has frequently touted his decision to close the US borders to China in an effort to curb the outbreak. Some health experts have said the effort bought time for the US to prepare, but the Trump administration has been accused of squandering the opportunity.

"Nobody except one country can be held accountable for what happened," Trump said.

"Nobody's blaming anybody here, we're looking at a group of people that should've stopped it at the source."

The US will never forget those who were "sacrificed for a reason of incompetence or something else other than incompetence," he added.

"They" - referring to China - "could've protected the whole world - not just us - the whole world," he said.

At the starting of the conference Trump said COVID-19 cases are declining or stablising across the country.

"In all cases getting better," he said. "Really a horrible situation that we've been confronted with, but they're moving along."

He added there's a "hunger" to get back to work.

"Ensuring the health of our economy is vital to ensuring the health of our nation - these goals work in tandem."

The president has suggested an unnamed individual "a long time ago" could have stopped the "unnecessary death[s]" due to COVID-19.

"There has been so much unnecessary death in this country," he said.

"It could've been stopped and it could've been stopped short, but somebody a long time ago, it seems, decided not to do it that way and the whole world is suffering because of it."

He did not say who he was referencing and gave no other details.

Trump was asked if he has considered delaying the November presidential election.

"I never even thought of changing the date of the election," he answered. "Why would I do that? November 3rd. That's a good number."

Trump called the suggestion "made up propaganda" and said that "sleepy Joe" Biden - his presumptive Democratic rival - was likely unaware his campaign had put the statement out.

Former Vice-President Joe Biden said at a virtual fundraiser last week that he thought Trump would "try to kick back the election somehow".

The president has frequently levelled insults at his Democratic opponent by questioning the former vice-president's mental fortitude.

"I look forward to that election," Trump said.

The president responded to a question criticising Health Secretary Alex Azar's early downplaying of the disease by saying it was "unfair". He claimed Democrats did the same, including Speaker of the House of Representatives Nancy Pelosi.

"I was very fortunate through luck or whatever that we closed the border, we put a ban on China," he said.

"But I could tell you that Nancy Pelosi was dancing in the streets in Chinatown. She wanted to go, let's go out and party. That was late in February."

Back in February, Pelosi had encouraged people to visit San Francisco's Chinatown to help struggling businesses. She did not propose any parties, as the president suggested.

The city issued a stay-at-home order in March.

A reporter asked: If an American president loses more Americans over the course of six weeks than died during the entirety of the Vietnam war, does he deserve to be reelected?

Trump took the question in stride.

"So, yeah, we've lost a lot of people but if you look at what original projections were, 2.2 million, we're probably heading to 60,000 - 70,000," he said.

"It's far too many - one person is too many for this. I think we've made a lot of really good decisions," he added. "The big decision was closing the border, doing the ban on people coming in from China."

He also brings up the "unbelievable" job his administration did with ventilators.

"I think we've done a great job. And I will say this - one person is too many."

London, Feb 12: Fugitive liquor baron Vijay Mallya returned to the courtroom here on Wednesday, the second day of hearing at the UK High Court, where the former billionaire has appealed against the extradition decision of Westminster Magistrates Court in December 2018.

On being asked about his expectations from the lengthy appeals process against the extradition order as today is the last day for Mallya to present his defence, the embattled former Kingfisher Airlines boss replied, "I have no clue. You see. I'll also see it. Let's not get into a speculative game."

When asked on what would happen if Mallya loses the case and has to return to India, the liquor baron responded: "We do have arguments."

The UK High Court, on Tuesday, had also heard Mallya's appeal against the Westminster Magistrates' Court order extraditing him to India to face alleged fraud and money laundering charges amounting to Rs 9,000 crore.

Mallya was present in the court along with his counsel Clare Montgomery during the hearing. Officials from Enforcement Directorate (ED) and Central Bureau of Investigation (CBI) along with counsel Mark Summers representing the Indian government were also present.

When the judge asked if there was a timeline in the case, Clare said," This is a very dense case," involving multiple individuals and organisations and that not everything had been taken into account by the magistrate Emma Arbuthnot in her ruling against Mallya.

Montgomery contended that the magistrate's ruling had been riddled with "multiple errors". She also brought into question the admissibility of documents submitted by the Indian government - including witness statements and emails that proved crucial in the ruling by judge Arbuthnot, who found "clear evidence of misapplication of loan funds" and that there was a prima facie case of fraud against Mallya.

As she had done throughout the trial, Montgomery continued to assert that Mallya had not acted in a fraudulent manner or run a pyramid and that the collapse of Kingfisher Airlines was, in fact, the failure of a business in difficult economic circumstances.

She also reiterated concerns about the conduct of the Central Bureau of Investigation (CBI) in bringing charges against Mallya, claiming that the tycoon had been made a scapegoat.

Montgomery also stated that the Indian government had presented the loan taken out by Kingfisher Airlines, not as a simple business loan but was part of a larger and elaborate attempt at defrauding the banks by Mallya and Kingfisher Airlines management.

This, Montgomery contended, was but one example of a wider misinterpretation of the case by judge Arbuthnot.

The High Court justices reprimanded Montgomery for concentrating on the evidence - in essence rehashing the case presented at the lower court - rather than the apparent "mistakes" made by judge Arbuthnot in her ruling.

Mallya remains on bail of £650,000 as he has done throughout this legal process.

The Crown Prosecution Service which is representing the Government of India will present its case for the extradition of Mallya on Wednesday.

The 63-year-old businessman fled India in March 2016 and has been living in the UK since then.

Canadian researchers are developing a DNA vaccine for SARS-CoV-2, the coronavirus that causes COVID-19 and has currently infected nearly 5,00,000 people worldwide and crippled the global economy.

Entos Pharmaceuticals, a health-care biotechnology company headed by a University of Alberta researchers, develop new therapeutic compounds using the company's proprietary drug-delivery platform and has begun manufacturing vaccine candidates against the novel coronavirus.

"Given the urgency of the situation, we can have a lead candidate vaccine within two months. Once we have that it's a race to get it into clinical trials," said John Lewis, CEO of Entos and a Professor at the University of Alberta in Canada.

Lewis said in comparison to a traditional vaccine, DNA-based vaccines hold several advantages.

Nucleic acids are introduced directly into the patient's own cells, causing them to make pieces of the virus--tricking the immune system into mounting a response without the full virus actually being present, the researcher said.

According to the company, the approach is recognised as being easier to move into large-scale manufacturing, offers improved vaccine stability and works without needing an infectious agent.

In the current absence of a vaccine for COVID-19, several companies around the world are mounting efforts to begin similar work.

The first clinical trial using a DNA-based vaccine developed by Moderna Inc.in the US on March 13.

Their approach allows for antibodies to be made in the human trial volunteers against a specific protein on the surface of the coronavirus that lets the virus enter human cells.

The hope is that the antibodies will stop the interaction.

Though this approach is designed to be effective against COVID-19 specifically, Lewis said Entos is taking a different tack.

The company plans to use plasmid DNA to amplify the production of key coronavirus surface and structural proteins with each injection, with an eye to the bigger picture.

"Many of the structural proteins in the virus are pretty well conserved across all the coronaviruses, including SARS and MERS," said Lewis.

"We're hoping that if we express more of the structural proteins that are common to most coronaviruses, we can inhibit the current COVID-19, and also potentially protect against all coronaviruses both past and future," Lewis added.

To move the project forward quickly, the company is seeking financial support from both provincial and federal levels of government.

"We have the opportunity to save a lot of lives, and I think it's really upon us and governments to find solutions for that," Lewis said.